Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0124136B2 - - Google Patents
[go: Go Back, main page]

JPH0124136B2 - - Google Patents

Info

Publication number
JPH0124136B2
JPH0124136B2 JP61243656A JP24365686A JPH0124136B2 JP H0124136 B2 JPH0124136 B2 JP H0124136B2 JP 61243656 A JP61243656 A JP 61243656A JP 24365686 A JP24365686 A JP 24365686A JP H0124136 B2 JPH0124136 B2 JP H0124136B2
Authority
JP
Japan
Prior art keywords
water
skin
bacteria
ppm
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP61243656A
Other languages
Japanese (ja)
Other versions
JPS6396130A (en
Inventor
Yoshiaki Matsuo
Jinichi Ito
Katsue Ooshima
Sugi Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP61243656A priority Critical patent/JPS6396130A/en
Priority to EP87305270A priority patent/EP0254413A3/en
Priority to KR870009489A priority patent/KR880002754A/en
Publication of JPS6396130A publication Critical patent/JPS6396130A/en
Publication of JPH0124136B2 publication Critical patent/JPH0124136B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

「技術分野」 本発明は、ヒト皮膚あるいは外腔粘膜等が細菌
等の病原菌に感染することによつて生起した皮膚
腫瘍疾患、扁桃腺症、歯槽膿漏症、毛髪疾患、壊
疽性病、じろう症などの病原菌性皮膚および外腔
粘膜疾患用の治療水に関する。 「従来技術およびその問題点」 近年、抗生物質、抗菌剤、化学療法剤等の開発
が長足の進歩をとげたことにより、内科外科を問
わず、細菌等の病原菌の感染による疾患に対して
高度の医療処置が行なわれるようになつたことは
事実である。また、以前は外科的手術によつてい
た治療が、内科的処理ですむようになり、これに
よつても充分な治癒を図れる症例も多い。しかし
ながら、一方で、広域抗生物質の大量投与によつ
て、耐性菌の臓器への定着を生み、難治感染症に
進展する症例が見受けられる。すなわち、日和見
感染症、菌交代症、院内感染症等の特殊な疾患や
風変りな感染症が次第に増加している現状があ
る。 また、皮膚病疾患のうち膨疹、水泡、膿泡、襄
胞、潰瘍等で内科を来診した患者で、診察の結
果、内臓疾患、例えば肝臓障害、腎障害、糖尿
病、あるいは胃腸、膵臓等の消化器関連疾患と
か、またはビタミン不足、内分泌ホルモン異常、
もしくはアレルギー疾患等によるものであると判
断された場合においては、これらに対する内科的
処置のみで終わつてしまい、いたずらに症状が長
びくことがある。これは、さまざまな内部疾患に
起因する皮膚表面の異常においては、少なくとも
健常なヒトからみると感染に対する抵抗力が弱ま
つている患者の皮膚、口腔内、消化器、外陰部等
のような外部と直接または間接に接する部位で、
該部位に生息している様々な定住性細菌または一
過性細菌などにより感染症が同時に引き起されて
いる虞れがあるものを、意外と度外視するため
に、知らず知らずのうちに難治感染症に追いやら
れるものである。すなわち、このような皮膚に
は、定住性細菌と一過性細菌が存在し、健常な皮
膚組織に対しての感染症はみられないが、一旦そ
のバランスがくずされた場合には、その皮膚異常
の原因が病原菌以外の場合であつても局所的に
は、常在菌叢からの単体または複合の感染にさら
されて病状が悪化していることが重要であり、内
因性疾患の場合の原因除去と共に皮膚面または粘
膜面における菌対策が平行して行なわれること
は、極めて重要な課題である。 ところで、現在用いられている化学療法剤は、
微生物に対する作用機序により以下の4つのタイ
プに分類される。すなわち、細菌細胞が動物細
胞とは異なり細胞壁をもつており、この細胞壁が
ペプチドグリカン層を含む2、3層からなるゆえ
に、トランスペプチダーゼの酵素活性を阻害して
ペプチドグリカン合成を阻害し、細胞壁の合成を
阻止して溶菌させる。例えばβ−グリカン系抗生
物質(ペニシリン、セフエム剤)、ホスホマイシ
ンなどのような細胞壁合成阻害性薬剤、病原菌
の細胞膜に障害を与え、細胞質内の各種イオン、
アミノ酸、核酸などを漏出させ、死滅させる、例
えばポリペプチド系抗生物質、ポリエン系抗生物
質(細菌には作用しない)、イミダゾール系抗真
菌剤などのような細胞(形質)膜阻害性薬剤(な
お、細胞膜は動物細胞とも共通しているため、こ
の作用をもつ薬剤は選択毒性が低く副作用が現わ
れやすい)、病原菌細胞のリボソームに作用し、
タンパク質合成を阻害する、例えばクロラムフエ
ニコール、マクロライド系抗生物質および類似
剤、テトラサイクリン系抗生物質、アミノ配糖
体、テトラサイクリン系抗生物質、アミノ配糖体
系抗生物質などのようなタンパク質合成阻害性薬
剤(なお、動物細胞のリボソームには作用が弱い
ので選択毒性には比較的優れる)、並びに例え
ばサルフア剤、ナリジクス酸および類似剤、フル
シトシン、リフアピシンなどのような核酸および
DNA合成阻害剤(多くは抗腫瘍性剤が含まれ、
細胞のみに作用する薬剤は選択毒性が高い)の4
つである。このように、今日の化学療法剤は、目
的別に上記の作用機序に基づき開発されており、
単独では幅広い抗菌スペクトラムが得られず、こ
のためしばしば併用して抗菌スペクトラムの拡大
を計つているが、これが耐性菌を生み、日和見感
染症などの難治感染症をもたらすこととなつてい
る。また、今日の化学療法剤は、上記の如く、そ
れぞれのジヤンルに従い生体に打撃を与えて損傷
させることにより、薬理作用をもたらすものが多
いが、LD50/ED50の安全率をとつてみても現世
代の生きている人間には、安全であつても次世代
または遺伝性について保障されているわけではな
い。 以上のような面から、ヒトの皮膚あるいは外腔
粘膜等が細菌などの病原菌に感染することによつ
て生起した病原菌性皮膚および外腔粘膜疾患の治
療法として、現在の化学療法剤に代わり、新たな
作用機序に基づく治療法が出現することが望まれ
ている。 「発明の目的」 したがつて、本発明は、新規な病原菌性皮膚お
よび外腔粘膜疾患用治療水を提供することを目的
とする。本発明は、また、自然生体系の機序に基
づき、病原菌を静菌殺菌し、さらに生体細胞の回
復の機序を促進し得る病原性皮膚および外腔粘膜
疾患用治療水を提供することを目的とする。本発
明は、さらに関与するであろう菌を静菌あるい
は滅菌する、破壊された組織を解体、吸収す
る、新生組織を速やかに再生するといつた3つ
の機序を同時に行なえ、かつ、無臭、無色、
速効性、簡易な病原性皮膚および外腔粘膜疾
患用治療水を提供することを目的とする。 「発明の構成」 上記諸目的は、PH5以下、Ag+イオン濃度0.5
〜10ppmのAg+イオン水からなる病原性皮膚およ
び外腔粘膜疾患用治療水によつて達成される。 また、本発明の好ましい実施態様においては、
治療水の電気伝導度は、350〜2000μ/cm3、溶
存酸素量は12〜30ppmである。 本発明の病原性皮膚および外腔粘膜疾患用治療
水(以下、単に治療水を呼称する)は、従来の治
療剤とは全く異なる機序に基づくものである。す
なわち、従来の治療剤は、上記したように、細
胞壁合成阻害、細胞質膜の阻害、タンパク質
合成阻害あるいは核酸およびDNA合成阻害と
いつた生体への阻害効果による薬効を示すもので
あり、自然の生体系における機序の中にその効果
を期待したものはなかつた。特に、細胞質膜の阻
害に至つては動物細胞と共通しているところが多
いため、副作用が現われやすく、その使用が極め
て限定される。そこで、本発明者らは、生体にお
ける細胞の消長を分析することにより初めて自然
の生体系の中に人為的な静菌細菌の機序を発見し
たものである。 すなわち、体を作る細胞の中には一度完成する
と寿命の続く限り生きつづける細胞もあれば、新
生と崩壊を繰り返すものまで多様であるが、細胞
が死滅するときの形態をみると、まず核に現われ
ることが多い。核に現われる変化とは、染色体の
濃縮であり、それとは対象的に細胞質に外部の水
分の流入により拡散が起こる。細胞は、細胞膜が
物質の出入を制御し、積極的に機能しているとき
が生であり、その機能が失われたときが死である
といえる。水の細胞質への流入の結果、膜の構造
物は空胞化しやがては破壊して形を失つてしま
い、小器官も放り出されて死に至る。しかしなが
ら、細胞質に多小の損害が加わつても核が充分に
機能すれば修復が可能である。これらの機序を分
析すると、細胞膜の機能を人為的に一時期失活す
る、すなわち細胞の形質膜を形成している組成に
対して特殊な触媒機能をもつて失活させれば目的
は達せられるが、反面動物に与える影響のないこ
とが前提となる。これまで、多くの実験と実証の
結果、我々はAgイオンのもつ
``Technical Field'' The present invention relates to skin tumor diseases, tonsillosis, alveolar pyorrhea, hair diseases, gangrene diseases, and pyorrhea caused by infection of human skin or external mucosa with pathogens such as bacteria. Concerning therapeutic waters for pathogenic skin and mucosal diseases such as. ``Prior art and its problems'' In recent years, the development of antibiotics, antibacterial agents, chemotherapeutic agents, etc. has made great progress, which has led to advanced treatments for diseases caused by infections caused by bacteria and other pathogens, regardless of whether it is medical or surgical. It is a fact that medical treatment has started to take place. In addition, treatment that used to be surgical can now be treated by internal medicine, and many cases can be cured satisfactorily by this method. However, on the other hand, there have been cases where large doses of broad-spectrum antibiotics lead to colonization of organs by resistant bacteria, which progresses to intractable infections. In other words, the number of special and exotic infections such as opportunistic infections, bacterial replacement, and nosocomial infections is gradually increasing. In addition, patients who visit an internal medicine department with skin diseases such as wheals, blisters, pustules, cysts, and ulcers may be diagnosed with internal organs, such as liver damage, kidney damage, diabetes, or gastrointestinal or pancreatic problems. Digestive related diseases, vitamin deficiencies, endocrine hormone abnormalities,
Alternatively, if it is determined that the cause is due to an allergic disease, etc., only medical treatment is required, which may unnecessarily prolong the symptoms. When it comes to abnormalities on the skin surface caused by various internal diseases, this is because the external organs such as the patient's skin, oral cavity, digestive system, vulva, etc., have weakened resistance to infection, at least from the perspective of healthy humans. A part that comes into direct or indirect contact with
In order to ignore the possibility that infections may be caused simultaneously by various resident bacteria or transient bacteria living in the area, people may unknowingly develop intractable infections. It is something that is driven away. In other words, in such skin, there are resident bacteria and transient bacteria, and no infection of healthy skin tissue is observed, but once the balance is disrupted, the skin becomes infected. Even if the cause of the abnormality is something other than pathogenic bacteria, it is important that the condition worsens locally due to exposure to single or combined infections from the resident flora, and in the case of an endogenous disease. It is an extremely important issue to eliminate the cause and take countermeasures against bacteria on the skin or mucous membranes in parallel. By the way, the currently used chemotherapeutic agents are
They are classified into the following four types depending on their mechanism of action against microorganisms. In other words, unlike animal cells, bacterial cells have a cell wall, and this cell wall consists of two or three layers, including a peptidoglycan layer. Inhibit and lyse. For example, drugs that inhibit cell wall synthesis such as β-glycan antibiotics (penicillin, cefem drugs) and fosfomycin, damage the cell membrane of pathogenic bacteria, and various ions in the cytoplasm.
Drugs that inhibit cell (plasma) membranes, such as polypeptide antibiotics, polyene antibiotics (does not act on bacteria), and imidazole antifungal agents, which leak and kill amino acids, nucleic acids, etc. Because the cell membrane is shared with animal cells, drugs with this effect have low selective toxicity and are more likely to cause side effects), and act on the ribosomes of pathogenic bacteria cells.
Protein synthesis inhibitors that inhibit protein synthesis, such as chloramphenicol, macrolide antibiotics and similar agents, tetracycline antibiotics, aminoglycosides, tetracycline antibiotics, aminoglycoside antibiotics, etc. Drugs (which have a weak effect on ribosomes in animal cells, so they have relatively good selective toxicity), and nucleic acids such as sulfur drugs, nalidixic acid and similar drugs, flucytosine, rifapicin, etc.
DNA synthesis inhibitors (many include antitumor agents,
Drugs that act only on cells have high selective toxicity) (4)
It is one. In this way, today's chemotherapeutic agents are developed based on the above-mentioned mechanisms of action for different purposes.
A broad antibacterial spectrum cannot be obtained when used alone, so they are often used in combination to expand the antibacterial spectrum, but this creates resistant bacteria and leads to opportunistic infections and other difficult-to-treat infections. Furthermore, as mentioned above, many of today's chemotherapeutic agents produce pharmacological effects by striking and damaging the living body according to their respective genres, but even when considering the safety factor of LD 50 / ED 50 , Even if it is safe for the current generation of living humans, it is not guaranteed for future generations or heritability. In view of the above, as a treatment for pathogenic skin and outer mucosal diseases caused by infection of the human skin or outer mucosa with pathogens such as bacteria, in place of current chemotherapeutic agents, It is hoped that a treatment method based on a new mechanism of action will emerge. ``Object of the Invention'' Therefore, the object of the present invention is to provide a novel therapeutic water for pathogenic skin and outer mucosal diseases. The present invention also aims to provide a therapeutic water for pathogenic skin and extraluminal mucosal diseases that can bacteriostatically kill pathogenic bacteria and further promote the recovery mechanism of living cells based on the mechanisms of natural biological systems. purpose. The present invention is capable of simultaneously performing three mechanisms: bacteriostatic or sterilizing bacteria that may be involved, disintegrating and absorbing destroyed tissue, and rapidly regenerating new tissue, and is odorless and colorless. ,
The purpose of the present invention is to provide a fast-acting, simple treatment water for pathogenic skin and extraluminal mucosal diseases. "Structure of the Invention" The above objectives are to have a pH of 5 or less, and an Ag + ion concentration of 0.5.
This is achieved by a therapeutic water for pathogenic skin and mucosal mucosal diseases consisting of ~10 ppm Ag + ionized water. Furthermore, in a preferred embodiment of the present invention,
The therapeutic water has an electrical conductivity of 350 to 2000 μ/cm 3 and a dissolved oxygen amount of 12 to 30 ppm. The therapeutic water for pathogenic skin and external mucosal diseases of the present invention (hereinafter simply referred to as therapeutic water) is based on a completely different mechanism from that of conventional therapeutic agents. In other words, as mentioned above, conventional therapeutic agents exhibit medicinal efficacy through inhibitory effects on living organisms such as inhibition of cell wall synthesis, inhibition of cytoplasmic membranes, inhibition of protein synthesis, or inhibition of nucleic acid and DNA synthesis. None of the mechanisms in the system were expected to have that effect. In particular, since they have many things in common with animal cells when it comes to inhibiting the cytoplasmic membrane, side effects are likely to occur, and their use is extremely limited. Therefore, the present inventors discovered for the first time the mechanism of artificial bacteriostatic bacteria in a natural biological system by analyzing the growth and development of cells in living organisms. In other words, among the cells that make up the body, there are a variety of cells, including those that continue to live for the duration of their lifespans once they are completed, and those that repeatedly regenerate and disintegrate. often appear. The change that appears in the nucleus is the condensation of chromosomes, in contrast to which diffusion occurs due to the influx of external water into the cytoplasm. A cell can be said to be alive when the cell membrane controls the entry and exit of substances and is actively functioning, and dead when that function is lost. As a result of the influx of water into the cytoplasm, membrane structures become vacuolated and eventually break down, losing their shape, and organelles are thrown out, leading to death. However, even if there is some damage to the cytoplasm, it can be repaired if the nucleus functions sufficiently. Analysis of these mechanisms shows that the goal can be achieved by artificially deactivating the cell membrane function for a period of time, that is, by deactivating the composition that forms the cell plasma membrane with a special catalytic function. However, the premise is that there is no impact on animals. As a result of many experiments and demonstrations, we have discovered that Ag ions have

【式】にの み働く機序を利用し、形質膜を構成するリン脂質
の不飽和脂肪酸に触媒してエチレン化することに
より、対象菌を失活させることに成功した。しか
も、Agイオン濃度によつて対象の菌を静菌化さ
せてもまた自由に復活させることに成功した。当
然タンパク質の混在において病原菌の体内にAg+
イオンを送り込むためには、途中タンパク質の錯
体結合によつてAg+イオン作用が低下してしまう
ことを防ぐ必要がある。そのために、錯体結合の
起こらないPH5以下の条件をつくると共に、電気
化学的にポテンシヤルを与え、たとえ菌体が芽胞
の形態をとろうともそのポテンシヤル勾配差を利
用して侵行せしめた。一方、Ag+イオン水の人体
に対する安全性について述べれば、例えば硝酸銀
の場合、マウスの経口投与におけるLD50は50
mg/Kgであることが確認されている。また、本願
発明におけるAg+イオン水と比べるとPHや濃度が
異なるが、カタデイン法と呼ばれる方法で製造さ
れた銀イオン水の場合、アメリカの衛生研究所の
テストにおいて人体に無害であることが判明し、
特定の州においては銀が0.2〜0.3mg/litre入つて
いる水を市民に供給していること、スイスではす
でに1930年ごろよりソフト・ドリンク工業で使用
されており、ドイツに導入されたときに多くの研
究所や大学で約5年間にわたりテストが行なわ
れ、衛生当局により製造装置の使用が認可された
こと、濃縮果汁で500〜1000γ/litre、清涼飲料
で300〜500γ/litreの銀イオンが添加されている
ことなどが既に知られている(「食品工業」、1965
年、11下、第84〜86頁、「銀による殺菌につい
て」、Dr.F.ゾブリスト参照)。本発明における
Ag+イオン濃度は、上記飲料に用いられた濃度よ
り約10倍程度高いのであるが、本発明の治療水
は、飲料のように多量に摂取するものではないの
で適正な使用によつて人体に対する安全性は充分
に確保される。 本発明の治療水をより具体的な作用に基づき詳
細に説明する。 動物細胞から病原菌である細菌、真菌、ウイル
ス、原虫等に至るまで、全ての細胞は細胞膜によ
つて取り囲まれており、これらの膜と生体との関
係は不充分で膜のないところに生命は存在しな
い。これらの生体膜は、各種の生命現象の基本的
な活動の源泉であり、膜内外における物質の濃度
あるいは電位差、存在様式の差異、他細胞におけ
る返撃等、複雑さの中に自然の秩序と合理的なメ
カニズムを合せもつて構成されている。 その生体膜の構造は、リン脂質よりなる二重膜
であり、これらのリン脂質のうち、ホスフアジル
セリン、ホスフアチジルエタノールアミンおよび
ホスフアチジルイノシトールは、主として膜の内
側に存在し、一方、ホスフアチジルコリンは膜の
外側に多い。 また、これらの生体膜に結合する膜結合性タン
パク質には、酵素活性をはじめ、種々の生理活性
を示すものが多く、その受容体またはイオンチヤ
ンネルや物質の輸送に関与するキヤリヤータンパ
ク質が含まれていることがよく知られている。 さて、細胞の物質構成を分析してみると、極性
脂質が25〜60%程度含まれており、脂質二重層と
膜タンパク質とで膜の基本構造をつくり上げてい
る。この中のリン脂質物は酸化されやすい多価の
不飽和脂肪酸に富んでいる。極性脂質分子の内、
親水性部分は直接水相と接し、電気抵抗値は102
〜105Ω/cm2と低い。一方、疎水部分は、脂肪酸
など−CH2−が多く疎水結合によつて互いに平行
に並び二重構造となつている。なお、動物細胞等
の真核細胞に比べ原核細胞と呼ばれる細菌などで
は生体膜の機能の多くは形質膜に集中するがその
組成は変わらない。また、真核細胞の細胞膜の細
胞質側には、細胞質膜を裏打ちするような細胞骨
格と呼ばれる繊維状のタンパク質の複合体があ
り、一方、原核細胞と真菌等の微生物には細胞膜
の外側に細胞壁があり、形態を保つている。さら
にウイルスなどの亜群においては、細胞(形質)
膜の外側表面に糖タンパク質またはリン脂質によ
るスパイク状のエンベロープを形成しているもの
もあり、これらが病床発現に大きな意味をもつこ
とになる。 ここで、細胞の失活は、細胞膜が関与している
実体から自然環境の中でも細胞膜そのものが失活
する様をみてみると、ペリフエリールイオン型物
質または・OHが膜のそばにできると、多価不飽
和脂肪酸のラジカルが生じ、ビラジカルの酸素と
結合して脂肪酸ペルオキシラジカルを生じ、次々
と加水分解を起こして膜は破裂する。この機序を
人為的に生起させ、対象菌を失活させるために
は、これらの化学反応を起こさせる触媒が必要で
あり、この機能を有する物質としては、銀以外は
見当らず、エチレンの酸化反応において部分酸化
生成物としてC2H4Oにする銀の触媒作用は他金
属で代替できない選択作用である。しかして、本
発明の治療水は、このような作用を有する銀を
Ag+イオンとして0.5〜10ppm、さらに望ましく
は1〜7ppm、もつとも望ましくは3〜6ppm含有
するものである。本発明の治療水中のAg+イオン
は、50Åから1000Åの巨大分子コロイド粒子のタ
ンパク質などを液体から分離通過せしめる機能を
有する細胞形質膜(ならびに細胞壁)を、電気化
学的ポテンシヤルによつて通過して菌体内に入
り、Ag+のもつ選択機能
Utilizing a mechanism that only works on [Formula], we succeeded in inactivating the target bacteria by catalyzing and ethyleneizing the unsaturated fatty acids in the phospholipids that make up the plasma membrane. What's more, even if the target bacteria were made bacteriostatic by adjusting the Ag ion concentration, they were able to revive them freely. Naturally, in the mixture of proteins, Ag +
In order to send ions, it is necessary to prevent the Ag + ion effect from decreasing due to complex binding of proteins during the process. To this end, we created conditions at a pH of 5 or below, where no complex binding occurs, and electrochemically provided a potential so that even if the bacterial cells take the form of spores, they can invade by utilizing the difference in potential gradient. On the other hand, regarding the safety of Ag + ionized water to humans, for example, in the case of silver nitrate, the LD 50 for oral administration to mice is 50.
It has been confirmed that mg/Kg. In addition, although the pH and concentration are different compared to the Ag + ion water of the present invention, silver ion water produced by a method called the Katadain method was found to be harmless to the human body in tests conducted by the American Institute of Health. death,
Certain cantons supply their citizens with water containing 0.2 to 0.3 mg/litre of silver, which has been used in the soft drink industry in Switzerland since around 1930, and when introduced to Germany. Tests have been carried out in many laboratories and universities for about five years, and the production equipment has been approved by health authorities. Silver ions are found to be 500 to 1000 γ/litre in concentrated fruit juice and 300 to 500 γ/litre in soft drinks. It is already known that food is added ("Food Industry", 1965
(See "On Sterilization by Silver," Dr. F. Zobrist, 2006, 11 vol., pp. 84-86). In the present invention
The concentration of Ag + ions is about 10 times higher than the concentration used in the above drinks, but since the therapeutic water of the present invention is not meant to be ingested in large quantities like a drink, it can be used properly to protect the human body. Safety is fully ensured. The therapeutic water of the present invention will be explained in detail based on more specific effects. All cells, from animal cells to pathogens such as bacteria, fungi, viruses, and protozoa, are surrounded by cell membranes, and the relationship between these membranes and living organisms is insufficient, and life cannot exist without membranes. not exist. These biological membranes are the source of the basic activities of various life phenomena, and the natural order is reflected in the complexity, such as the concentration or potential difference of substances inside and outside the membrane, differences in the mode of existence, and counterattacks in other cells. It is constructed with a rational mechanism. The structure of the biological membrane is a double membrane composed of phospholipids, and among these phospholipids, phosphadylserine, phosphatidylethanolamine, and phosphatidylinositol exist mainly on the inside of the membrane; Phosphatidylcholine is abundant on the outside of the membrane. In addition, many of these membrane-bound proteins that bind to biological membranes exhibit various physiological activities, including enzymatic activity, and include their receptors, ion channels, and carrier proteins involved in the transport of substances. It is well known that Now, when we analyze the material composition of cells, we find that they contain about 25 to 60% polar lipids, and the basic structure of the membrane is made up of a lipid bilayer and membrane proteins. Among these, phospholipids are rich in polyunsaturated fatty acids that are easily oxidized. Among polar lipid molecules,
The hydrophilic part is in direct contact with the water phase, and the electrical resistance value is 10 2
As low as ~10 5 Ω/cm 2 . On the other hand, the hydrophobic part has a double structure in which -CH 2 -, such as fatty acids, are arranged parallel to each other by hydrophobic bonds. Note that, compared to eukaryotic cells such as animal cells, in prokaryotic cells such as bacteria, many of the functions of biological membranes are concentrated in the plasma membrane, but its composition remains unchanged. Furthermore, on the cytoplasmic side of the cell membrane of eukaryotic cells, there is a fibrous protein complex called the cytoskeleton that lines the cytoplasmic membrane, while prokaryotic cells and microorganisms such as fungi have a cell wall on the outside of the cell membrane. There is, and it maintains its shape. Furthermore, in subgroups such as viruses, cells (plasma)
Some of them have spike-like envelopes made of glycoproteins or phospholipids on the outer surface of their membranes, and these have great significance in disease bed expression. Here, cell inactivation is an entity that involves the cell membrane, and if we look at how the cell membrane itself is inactivated even in the natural environment, it can be seen that when peripheryel ion type substances or OH are formed near the membrane. Radicals of polyunsaturated fatty acids are generated, which combine with the oxygen of biradicals to produce fatty acid peroxyl radicals, which undergo hydrolysis one after another and rupture the membrane. In order to artificially create this mechanism and deactivate the target bacteria, a catalyst is required to cause these chemical reactions, and there is no substance other than silver that has this function, and ethylene oxidation The catalytic action of silver to form C 2 H 4 O as a partial oxidation product in the reaction is a selective action that cannot be replaced by other metals. Therefore, the therapeutic water of the present invention contains silver that has such an effect.
It contains 0.5 to 10 ppm, more preferably 1 to 7 ppm, and most preferably 3 to 6 ppm of Ag + ions. The Ag + ions in the treatment water of the present invention pass through the cell plasma membrane (as well as the cell wall) by electrochemical potential, which has the function of separating proteins and other macromolecular colloidal particles of 50 Å to 1000 Å from the liquid. Enters the bacterial body and has the selective function of Ag +

【式】の触媒機能 により細胞膜の機能を失活させる。我々が行なつ
た実験によるとAg+イオン濃度が100〜500ppb程
度では、一時静菌された菌体が再び再生増殖を始
め、濃度が増すにつれ、再生率が下がり、濃度が
0.5〜10ppmになると殆ど滅菌状態となることが
明らかとなつたものである。また、病原菌におか
された細胞は菌体とほぼ同じ傾向をたどる注目す
べき現象が発見された。したがつて、本発明の治
療水で処置することにより、病原菌を失活せしめ
ると同時に、病原菌によりおかされた組織を解体
することができ、このような組織による組織再生
の阻害をも取り除くことができるものである。一
方、正常な組織細胞に対しては何ら悪影響を及ぼ
すことなく、皮膚に比して抵抗力の弱い粘膜部に
おいても何ら問題のないものであつた。 また、本発明の治療水において、そのPH値は5
以下であるが、さらに望ましくはPH4以下、もつ
とも望ましくはPH3以下である。このように治療
水のPH値を5以下とすることで、Ag+イオンのタ
ンパク質への吸着を防止でき、タンパク質の共存
条件下においてもAg+イオンの触媒作用の低下を
防止し、Ag+イオンが対象菌体の形質膜を自由に
透過することを可能とする。 さらに、本発明の治療水においては、電気伝導
度が350〜2000μ/cm3、さらに望ましくは1000μ
/cm3以上、もつとも望ましくは1500μ/cm3
上であることが好ましい。このように電気伝導度
を350〜2000μ/cm3とすることにより、Ag+イオ
ンの細胞透過性はより良好なものとなり、Ag+
オンの作用を充分に発現させることができるもの
となる。 加えて、本発明の治療水において、溶存酸素量
を12〜30ppmとすることは、患部組織の修復再生
に好ましい環境をもたらすものである。 本発明者らは、まずPH5以下、Ag+イオン濃度
0.5〜10ppm、電気伝導度300〜2000μ/cm3、溶
存酸素量12〜30ppmのAg+イオン水を下記に述べ
るようにして製造し病原菌性(黄色ブドウ球菌
性)皮膚疾患を起こしている患部に浸水させたと
ころ、従来の化学治療剤には見られない劇的な効
果をもたらした。そこでさらに、アセモ、頭部粃
糖症、壊疽病、リン病、歯槽膿漏、水虫等の疾患
に適用したところ、被症部分の病原菌体の種類に
かかわらず、いずれも菌体は1日程度で死滅し、
疼痛は治療後直ちに解消され、さらに止血効果を
もたらし、傷ついた細胞は分解吸収され健常な細
胞のみで再生が始まり、活性酸素の供給等により
驚異的な回復力を示し、24〜50時間後には接触屈
伸を行なつてもなんら支障を感じないほどの治療
効果を上げるに至つた。 なお本発明の治療水を銀コロイドを生じること
なく製造するには、例えば本発明者らが先に見出
したように(昭和61年特許願第123133号参照)、
陽極と陰極とを有し、陽極に銀が設けられた第1
電解室に電圧を印加しつつ源水を通じて銀イオン
を溶出させ、次に陽極と陰極とを有し、両電極の
間に隔膜が形成され、陽極室と陰極室とに区画さ
れた第2電解室の前記陽極室に、前記銀イオンを
溶出させた源水を通すことにより好適に行ない得
る。 「発明の実施例」 以下本発明を実施例によりさらに具体的に説明
する。 実施例 1 (症状)うつけつ性湿疹 静脈瘤のある下肢。潮紅の強い湿潤性有り。一
部自家感染作性皮膚炎を起こしている。 (処置) PH3、Ag+イオン濃度3ppm、電気伝導度1000μ
/cm3、溶存酸素濃度15ppmのAg+イオンを患部
に塗布し、事後30分間同Ag+イオン水で湿布す
る。 (効果) 治療後5分で掻痒感はなくなり、30分後潮紅性
がなくなり、1日で正常皮膚となつた。 実施例 2 (症状)急性痒疹小児ストロフイルス 紅斑と膨疹があり、掻被のため小水疱が四肢と
体幹にみられる。 (処置) PH3、Ag+イオン濃度3ppm、電気伝導度1000μ
/cm3、溶存酸素量15ppmのAg+イオン水を全身
にスプレーしたのち、同Ag+イオン水で冷湿布と
行なつた。 (効果) 掻痒感と疼痛は治療後10分程度で消え、24時間
後には膨疹が引き、皮膚の掻被のあともほとんど
消失し、3日後に完全治癒した。 実施例 3 (症状)膿疱性乾癬 紅皮症状態、粘膜症状あり、口内炎も併発し、
手皮膚面に落屑がみられる。 (処置) PH4、Ag+イオン濃度4ppm、電気伝導度800μ
/cm3、溶存酸素量20ppmのAg+イオン水をスプ
レーしたのち、同Ag+イオン水で湿布する。口腔
内は、同Ag+イオン水をうがいのために提供し、
1日3回のうがいを指示した。 (効果) 粘膜症状は1日で治癒し、紅皮状態は3日後に
うすれ平常皮に戻つた。口腔内炎症は12時間で完
治した。 実施例 4 (症状)禿髪性毛包炎 毛包に膿疹が生じ、つぎつぎと隣接毛包に波及
している。菌体スポトリコーンス。 (処置) PH4、Ag+イオン濃度4ppm、電気伝導度800μ
/cm3、溶存酸素量20ppmのAg+イオン水をスプ
レーガンで霧状に散布し、マツサージを行なう。 (効果) フケ状癜皮は、治療後1日でとれ、3日後、3
回のスプレーでほとんど完治状態となつた。 実施例 5 (症状)単純性疱疹 紅暈を伴なつた小水泡が習俗仕手発疹、一部び
らん状態を呈す。ウイルス性疾患。 (処理) PH4、Ag+イオン濃度4ppm、電気伝導度800μ
m/cm3、溶存酸素量20ppmのAg+イオン水を含
浸して湿布し、1時間程度にて数回取り換える。 (効果) ピリピリした感じが処置後5分程でとれ、24時
間後水泡はほとんど引き、皮膚表面の緊張度も戻
つた。その後の再発はみられなかつた。 実施例 6 (症状)尖毛コンジローマ 陰唇肛囲に症状丘疹、表面浸軟し悪臭が強く、
硬性下疳合併症、ウイルス性疾患。 (処置) PH4、Ag+イオン濃度4ppm、電気伝導度800μ
/cm3、溶存酸素量20ppmのAg+イオン水を水盆
に満たし約2時間浸漬した。 (効果) 2時間後悪臭が消え、浸軟による摩擦の痛みは
なくなる。3日間通院後、表面的症状はとれ、癜
痕が落脱し、5日で下疳症状は完治した。 実施例 7 (症状)足白癬(みずむし) 趾間、特に第4趾間の皮膚が浸軟し、赤色びら
んと亀裂がある。白癬菌。 (処置) PH2.5、Ag+イオン濃度5ppm、電気伝導度
1500μ/cm3、溶存酸素量15ppmのAg+イオン水
をバツケツトに入れ、足を1時間延ぶ30分間浸漬
を実施後、同Ag+イオン水の湿布をして24時間後
停止。 (効果) 浸漬1時間後足裏の痛みは完全になくなり、24
時間後、亀裂はふさがり、白いコラーゲン状の肉
芽と表皮が形成されており、3日間湿布を続け時
後の再発は見られなかつた。 実施例 8 (症状)歯槽膿漏(近縁性歯周炎) 歯周ポケツトの混合菌感染でうつ血、歯肉炎を
続発し、一部で出血が見られ、口臭が強い。 (処置) PH3、Ag+イオン濃度4ppm、電気伝導度1100μ
/cm3、溶存酸素量12ppmのAg+イオン水でうが
いをした後、綿に浸した同Ag+イオン水で菌肉周
囲をたんねんに付加し、再びうがいを励行さす。
うがい水として同Ag+イオン水を1日分渡す。 「発明の効果」 以上述べたように、本発明の病原菌性皮膚およ
び外腔粘膜疾患治療水は、PH5以下、Ag+イオン
濃度0.5〜10ppmのAg+イオン水からなるもので
あるから、抗菌スペクトラムが広く関与するであ
ろう菌をことごとく静菌あるいは滅菌し、破壊さ
れた組織を解体吸収し、新生組織をすみやかに再
生するといつた3つの機序を同時に行なうといつ
た従来の化学治療剤とは全く異なる作用機序によ
り、治療を行ない、かつ無臭、無色、速効性およ
び簡易といつた要件を備えた優れた治療水であ
り、ヒトの皮膚あるいは外腔粘膜等が、細菌等の
種々の病原菌に感染することによつて生起した皮
膚腫瘍疾患、扁桃腺症、歯槽膿漏症、毛髪疾患、
壊疽性病、じろう症などのあらゆる病原菌性皮膚
および外腔粘膜疾患の治療に好ましく用いられ得
るものである。
The catalytic function of [Formula] deactivates the function of cell membranes. According to our experiments, when the Ag + ion concentration is around 100 to 500 ppb, temporarily bacteriostatic bacterial cells begin to reproduce and proliferate again, and as the concentration increases, the regeneration rate decreases and the concentration decreases.
It has become clear that when the concentration is 0.5 to 10 ppm, it becomes almost sterile. In addition, a remarkable phenomenon was discovered in which cells infected by pathogens follow almost the same tendency as bacterial bodies. Therefore, by treatment with the therapeutic water of the present invention, it is possible to deactivate pathogenic bacteria and at the same time dismantle tissues damaged by pathogenic bacteria, and also remove the inhibition of tissue regeneration caused by such tissues. It is possible. On the other hand, there was no adverse effect on normal tissue cells, and there were no problems even in mucous membranes, which have a weaker resistance than the skin. In addition, the therapeutic water of the present invention has a PH value of 5
The pH is below, more preferably PH4 or below, and even more preferably PH3 or below. In this way, by setting the PH value of the treatment water to 5 or less, it is possible to prevent Ag + ions from being adsorbed to proteins, and even in the coexistence of proteins, the catalytic activity of Ag + ions is prevented from decreasing . allows it to freely pass through the plasma membrane of the target bacterial cell. Furthermore, the therapeutic water of the present invention has an electrical conductivity of 350 to 2000 μ/cm 3 , more preferably 1000 μ/cm 3 .
/cm 3 or more, most preferably 1500 μ/cm 3 or more. By setting the electrical conductivity to 350 to 2000 μ/cm 3 in this way, the cell permeability of Ag + ions becomes better, and the action of Ag + ions can be fully expressed. In addition, in the therapeutic water of the present invention, setting the amount of dissolved oxygen to 12 to 30 ppm provides a favorable environment for repair and regeneration of affected tissues. The present inventors first determined that the pH is below 5 and the Ag + ion concentration.
Ag + ionized water with an electrical conductivity of 0.5 to 10 ppm, an electrical conductivity of 300 to 2000 μ/cm 3 , and a dissolved oxygen content of 12 to 30 ppm is produced as described below and applied to the affected area of pathogenic (Staphylococcus aureus) skin disease. When immersed in water, it produced dramatic effects not seen with conventional chemical treatments. Therefore, when applied to diseases such as acemocytosis, cephalic acidosis, gangrene, Lin's disease, alveolar pyorrhea, and athlete's foot, it was found that regardless of the type of pathogenic bacteria in the affected area, the bacteria remained for about 1 day. died in
The pain is immediately resolved after treatment, and it also has a hemostatic effect. Damaged cells are broken down and absorbed, and only healthy cells begin to regenerate. Due to the supply of active oxygen, etc., it shows amazing recovery power, and within 24 to 50 hours, The therapeutic effect has been achieved to the extent that there is no problem even when performing contact bending and stretching. In order to produce the therapeutic water of the present invention without producing silver colloid, for example, as previously discovered by the present inventors (see Patent Application No. 123133 of 1988),
The first electrode has an anode and a cathode, and the anode is provided with silver.
Silver ions are eluted through the source water while applying a voltage to the electrolytic chamber, and then a second electrolytic chamber is formed which has an anode and a cathode, a diaphragm is formed between the two electrodes, and is divided into an anode chamber and a cathode chamber. This can be suitably carried out by passing source water in which the silver ions have been eluted through the anode chamber of the chamber. "Examples of the Invention" The present invention will be described in more detail below with reference to Examples. Example 1 (Symptoms) Depressive eczema Lower limbs with varicose veins. Has strong moisturizing properties with flushing. Some cases of autologous dermatitis. (Treatment) PH3, Ag + ion concentration 3ppm, electrical conductivity 1000μ
Apply Ag + ions with a dissolved oxygen concentration of 15 ppm to the affected area, and then apply a compress with the same Ag + ion water for 30 minutes. (Effects) The itching sensation disappeared 5 minutes after treatment, the flushing disappeared 30 minutes later, and the skin returned to normal within 1 day. Example 2 (Symptoms) Acute prurigo strophilus in children There was erythema and wheal, and vesicles were observed on the extremities and trunk due to scratching. (Treatment) PH3, Ag + ion concentration 3ppm, electrical conductivity 1000μ
After spraying Ag + ion water with a dissolved oxygen content of 15 ppm over the whole body, a cold compress was applied with the same Ag + ion water. (Efficacy) The itching and pain disappeared within about 10 minutes after treatment, the wheal subsided after 24 hours, the scratching on the skin almost disappeared, and the patient was completely healed after 3 days. Example 3 (Symptoms) Pustular psoriasis Erythroderma, mucous membrane symptoms, stomatitis also occurred,
Desquamation is seen on the skin of the hands. (Treatment) PH4, Ag + ion concentration 4ppm, electrical conductivity 800μ
/cm 3 , and after spraying Ag + ion water with a dissolved oxygen amount of 20 ppm, apply a poultice with the same Ag + ion water. In the oral cavity, provide the same Ag + ionized water for gargling.
The patient was instructed to gargle three times a day. (Effects) The mucous membrane symptoms were cured within one day, and the erythematous skin condition faded and returned to normal skin after three days. The oral inflammation completely resolved within 12 hours. Example 4 (Symptoms) Folliculitis baldness A purulent eruption occurs in the hair follicle, which gradually spreads to adjacent hair follicles. Mycobacterium Spotolicones. (Treatment) PH4, Ag + ion concentration 4ppm, electrical conductivity 800μ
/cm 3 and 20 ppm of dissolved oxygen in the form of a mist of Ag + ion water using a spray gun to perform pine surge. (Efficacy) The dandruff-like skin disappears within 1 day after treatment, and after 3 days,
After just one spray, I was almost completely cured. Example 5 (Symptoms) Herpes simplex A rash of small blisters accompanied by red halos, with some erosions. Viral disease. (Processing) PH4, Ag + ion concentration 4ppm, electrical conductivity 800μ
m/cm 3 , and a poultice impregnated with Ag + ionized water with a dissolved oxygen content of 20 ppm, and replaced several times every hour or so. (Effects) The tingling sensation disappeared within about 5 minutes after the treatment, and 24 hours later, most of the blisters had subsided and the skin's surface tension had returned. No recurrence was observed thereafter. Example 6 (Symptoms) Condyloma acuminata Symptoms: Papules around the labia and anus, the surface is macerated, and there is a strong odor.
Chancroid complications, viral diseases. (Treatment) PH4, Ag + ion concentration 4ppm, electrical conductivity 800μ
A water basin was filled with Ag + ion water with a concentration of 20 ppm and a dissolved oxygen content of 20 ppm, and the water was immersed for about 2 hours. (Effect) After 2 hours, the bad odor disappears and the pain caused by friction due to maceration disappears. After visiting the hospital for 3 days, the superficial symptoms disappeared, the scars fell off, and the chancre symptoms were completely cured in 5 days. Example 7 (Symptoms) Tinea pedis (athlete's foot) The skin between the toes, especially the fourth toe, was macerated, with red erosion and cracks. Trichophyton. (Treatment) PH2.5, Ag + ion concentration 5ppm, electrical conductivity
Put Ag + ion water with 1500μ/cm 3 and dissolved oxygen content of 15 ppm into a bucket, soak the feet for 30 minutes for 1 hour, apply a compress with the same Ag + ion water, and stop after 24 hours. (Effect) After 1 hour of soaking, the pain in the soles of my feet completely disappeared, and after 24 hours
After some time, the fissure had closed, and white collagen-like granulation and epidermis had formed, and no recurrence was observed after 3 days of continued use of the compress. Example 8 (Symptoms) Alveolar pyorrhea (proximal periodontitis) A mixed bacterial infection of the periodontal pockets resulted in congestion and gingivitis, with bleeding seen in some areas and strong bad breath. (Treatment) PH3, Ag + ion concentration 4ppm, electrical conductivity 1100μ
After gargling with Ag + ionized water containing 12 ppm of dissolved oxygen per cm 3 , soak cotton in the same Ag + ionized water and thoroughly apply the bacteria around the meat and gargle again.
Give one day's supply of the same Ag + ionized water as gargling water. "Effects of the Invention" As described above, the water for treating pathogenic skin and external mucosal diseases of the present invention is composed of Ag + ion water with a pH of 5 or less and an Ag + ion concentration of 0.5 to 10 ppm, so it has a good antibacterial spectrum. Conventional chemotherapeutic agents that simultaneously perform three mechanisms: bacteriostasis or sterilization of all bacteria that are likely to be widely involved, disintegration and absorption of destroyed tissues, and prompt regeneration of new tissues. It is an excellent therapeutic water that provides treatment through a completely different mechanism of action and has the following requirements: odorless, colorless, fast-acting, and simple. Skin tumor diseases caused by infection with pathogenic bacteria, tonsillosis, alveolar pyorrhea, hair diseases,
It can be preferably used for the treatment of all pathogenic bacterial skin and extraluminal mucosal diseases such as gangrene and sclerosis.

Claims (1)

【特許請求の範囲】 1 病原菌に感染することによつて生起した病原
菌性皮膚および外腔粘膜疾患用治療水において、
PH5以下、Agイオン濃度0.5〜10ppmのAg+イオ
ン水からなる病原菌性皮膚および外腔粘膜疾患用
治療水。 2 電気伝導度が350〜2000μ/cm3、溶存酸素
量が12〜30ppmである特許請求の範囲第1項に記
載の病原菌性皮膚および外腔粘膜疾患用治療水。
[Scope of Claims] 1. Treatment water for pathogenic skin and external mucosal diseases caused by infection with pathogenic bacteria,
Treatment water for pathogenic skin and external mucosal diseases consisting of Ag + ion water with a pH of 5 or less and an Ag ion concentration of 0.5 to 10 ppm. 2. The therapeutic water for pathogenic skin and extraluminal mucosal diseases according to claim 1, which has an electrical conductivity of 350 to 2000 μ/cm 3 and a dissolved oxygen content of 12 to 30 ppm.
JP61243656A 1986-06-13 1986-10-14 Water for curing pathogenic bacterial disease of skin and external cavity membrane Granted JPS6396130A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP61243656A JPS6396130A (en) 1986-10-14 1986-10-14 Water for curing pathogenic bacterial disease of skin and external cavity membrane
EP87305270A EP0254413A3 (en) 1986-06-13 1987-06-12 Silver-ionic water and its uses
KR870009489A KR880002754A (en) 1986-08-29 1987-08-29 Hot water and its uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61243656A JPS6396130A (en) 1986-10-14 1986-10-14 Water for curing pathogenic bacterial disease of skin and external cavity membrane

Publications (2)

Publication Number Publication Date
JPS6396130A JPS6396130A (en) 1988-04-27
JPH0124136B2 true JPH0124136B2 (en) 1989-05-10

Family

ID=17107056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61243656A Granted JPS6396130A (en) 1986-06-13 1986-10-14 Water for curing pathogenic bacterial disease of skin and external cavity membrane

Country Status (1)

Country Link
JP (1) JPS6396130A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014200778A (en) * 2013-04-10 2014-10-27 至明 松尾 Antioxidative drinking water
CN110972590B (en) * 2019-10-12 2021-04-20 浙江大学 A method and device for realizing soil propelled in-situ nitrogen fixation using low-temperature plasma technology
CN111661854B (en) * 2020-05-08 2021-04-20 浙江大学 A nitrogen oxide absorption and utilization system based on low temperature plasma catalytic nitrogen fixation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376764A (en) * 1981-08-10 1983-03-15 Basf Wyandotte Corporation Silver ion gel compositions
EP0136768A3 (en) * 1983-09-07 1986-07-30 Laboratorios Biochemie De Mexico S.A. DE C.V. Composition and method for treatingskin lesions

Also Published As

Publication number Publication date
JPS6396130A (en) 1988-04-27

Similar Documents

Publication Publication Date Title
Di Paolo et al. Ozone therapy
EP2200441B1 (en) Composition and method for the prevention of oral disease
US5334383A (en) Electrically hydrolyzed salines as in vivo microbicides for treatment of cardiomyopathy and multiple sclerosis
ES2701153T3 (en) Method to treat skin ulcers using a solution with water of oxidative reductive potential
US6426066B1 (en) Use of physiologically balanced, ionized, acidic solution in wound healing
US20090227523A1 (en) Use of compatible solutes as substances having free radical scavenging properties
GB2355190A (en) Super-oxidised water based on hypochlorous acid in medical treatment
US20080020025A1 (en) Composition for wound care and method of using same
Néri et al. Ozone therapy influence in the tissue repair process: a literature review
WO1995014484A1 (en) In vivo free-radical generator
JPWO1995014484A1 (en) In vivo free radical generators
EP1959972A2 (en) Method of treating open wounds using hypochlorous acid
Harris et al. The development and evaluation of melatonin-loaded, calcium oxide nanoparticle-based neem and clove extract: an in vitro study
JP5434915B2 (en) Helicobacter pylori disinfectant
JPH0124136B2 (en)
Abbott Treatment of warts with bleomycin
US20180110803A1 (en) Neutral Electrolyzed Water and Uses Thereof
EP1663195B1 (en) Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition
US6932966B1 (en) Topically applied reconstituted ocean water mixture and method of producing and using the mixture
JPH0124134B2 (en)
CA2299205A1 (en) Super-oxygenated water solutions and methods of use
RU2306939C1 (en) Method for treating furunculosis cases
Pan et al. Mechanism and clinical application of ozone therapy in treating skin ulcer diseases
RU2344812C1 (en) Method of infected wound treatment for carnivorous animals
KR20250108665A (en) Hypochlorite solution for scar tissue treatment